Koyfin Home > Directory > Health Care > Adverum Biotechnlgs > Long-Term Debt

Adverum Biotechnlgs Long-Term Debt Chart (ADVM)

Adverum Biotechnlgs annual/quarterly Long-Term Debt from 2014 to 2019.
  • Adverum Biotechnlgs Long-Term Debt for the quarter ending December 12, 2019 was $0m a 26.00% increase of 0m year over year
  • Adverum Biotechnlgs Long-Term Debt for the last 12 months ending December 12, 2019 was $0m a 26.00% increase of 0m year over year
  • Adverum Biotechnlgs Annual Long-Term Debt for 2019 was $0m a -100.00% decrease of 0m from 2018
  • Adverum Biotechnlgs Annual Long-Term Debt for 2018 was $0m a -128.50% decrease of 0m from 2017
  • Adverum Biotechnlgs Annual Long-Term Debt for 2017 was $0m a 83.81% increase of 0m from 2016
Other Cash Flow Metrics:
  • Adverum Biotechnlgs Cash Flow from Operations for the quarter ending December 12, 2018 was $-13m a -2.00% increase of 0m year over year
  • Adverum Biotechnlgs Levered Free Cash Flow (FCF) for the quarter ending December 12, 2018 was $-26m a 70.14% decrease of -18m year over year
  • Adverum Biotechnlgs Total Revenue for the quarter ending September 09, 2018 was $1m a 44.66% increase of 0m year over year
View Chart On Koyfin

Quarterly ADVM Long-Term Debt Data

12/2019$0m
12/2018$0m
12/2017$0m
09/2017$0m
06/2017$0m
03/2017$0m
12/2016$0m
09/2016$0m
03/2014$0m

Annual ADVM Long-Term Debt Data

2019$0m
2018$0m
2017$0m
2016$0m
2012$0m